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Introduction. Administration of the broad sp«:ific proleinase 
inhibitor aprotinin (Trasylol) is recommended as part of the 
therapeutic regimen of various diseascs, e.g. in shock syndromes, 
hypcrfibrinolysis or acute pancn~atitis [I]. However, the attempt 
to demonstrate clinical efTeclivencss of aprotinin therapy by 
prospcctive controllcd dinical trials has proved to bc extremely 
difficult, probably duc to the lack of an assay system allowing a 
reliableestimation of effective inhibitor conccntrations in plasma 
(1]. Wc have established a chromogenic peptide subSlrate assay 
convenient for monitoring the inhibitory effectivcness of apro_ 
tinin in plasma samples of paticnts undergoing inhibitor therapy. 
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Fig, 1. Standard curve for the determination of aprotinin in 
plasma (details see text) 
corrcsponding to 200 KI U/ml untreated plasma) by dilu tion of 
Ihis stock solution with aprotinin-frec normal plasma. 
3. Photomelrie A ssay. Tbe reaction mixture is prepared by 
pipetting the sampies in the .following order into therr':lOstated 
(37° C) I-ml-cuvettes placed III a photometer: 855 Jl I Tns buffer 
(0.2 M, pH 8.2), 25 jll acid-treated normal plasma (" blank") or 
aprotinin-containing.plasma (standard or ~a~ents' sa.mples), a~d 
20111 kallikreinsolullOn (1 K U). After 5mlllllleub~lIon ~1 37 C 
100 Jl l S-2266 solution (1.5 mM) is added and thc hnear lI~crease 
in absorbancc at 405 nm read eontinuously for at least 3 mm. The 
free enzyme aetivity (LlAjmin) of thc sampie is eale~l~t~d in 
pcrcent of the "blank". The percent of free enzyme actlv~tlcs of 
thc standard sampies are plotted against their conccntratlOns of 
aprotinin, and the inhibitory aetivity of aprotinin in the patients' 
plasma is calculated from this standard curve. 
Rcsul ts and Discussion. Evaluation oj the Assay. According to the 
standard eurve (Fig. I) the lowest accurately measur~ble amount 
of aprotinin is about 20 kal1ikrein inhibitor units (KIU)/ml 
plasma (before acid treatment), i.e. 0.25 KJU per a~ay. If the 
aproti nin amount excecds 0.75 - 1.0~JU per. as~ay, I?l~sm.a 
sampies should be diluted as folIows. Smce kall lkrem aCllvlty lS 
elevated l.23-fold (n = 90; C.V. = 7.2%) by addition of acid-
Assay Principlc. In eontrast to endogcnous plasma proteinase 
inhibitors. aprotinin (Trasylol) is a very potent immediate 
inhibitor of porcine panereatic kallikrein (tissue kallikrein). Duc 
to acid treatment of plasma sampies obtained after i.v. infusion 
of aprotinin in vivo or addition oflhe inhihitor in vitro, aprotinin 
is the only measurable tissue kallikrcin inhibitor in these 
specimens. After ineubation of acid-trcated plasma with tissuc 
kallikrein in excess ovcr aprotinin, the remaining amount ofthe 
enzyme is determined by its amidolytic activity on the substrate 
H-D-Val-Leu-Arg-p NA (S-2266). The ratc at which pNA is 
rclcased is measured pholometrical1y at 405 nm with the jnitial 
rate method. Under the given eonditions thc substrate recognizcs 
exelusively the tissue kallikrein applied. 
Reagents. 5-2266 is manufactured by Aß Kabi Diagnostica, 
Stockholm, Sweden. Poreine pancreatic kallikrein is available 
as a lyophilized research product from Bayer AG, Wuppcr-
tal-Elbcrfeld. FRG: Kininogenase Standard Pt. 2208 L 
(512.5 KU/ampoule). A stock solution of I KU/J-ll is preparcd by 
dissolving the residue in sterile 0.9% NaCI solution adjusted to 
pH 7.5 with lriethanolamine. AprOlinin (Trasylol) for prcpara-
tion of the standard curve is purchased as a sterile isotonic 
solution (ampoulc5 of200,OOO KIU/I 0 ml, pH 5) from Bayer AG, 
Leverkusen, FRG. 
Procedure. J. Acid Tremment oj Plasma. Normal plasma or 
patients' plasma is incubated for 10min al 25°C with an equal 
volurne of 3 % (wjv) perchloric acid. After centrifugation the 
supernatant is neutralized with 5 M K2C0 3, kepl at 4 - 8°C for 
furthe r 30min and theTeafter cenuifuged again. The rcsulting 
supernatant is frozen at _20°C or bclow. 
2. Standard Cun'e. An samples are aeid-treated bcfore further 
use. Standard sampies are madc up from normal plasma 
supplemented with aprotinin (I00K IU/ml acid-treated plasma 
treated normal plasma, all dilutions of aprotinin~containing 
plasma sampies must bc made by aprotinin-frccplasma. Thereby 
always thc same amount of plasma (25 J-l1) is added to the test 
system. Dilution with buffeT or isotonic saline sol ution instead of 
plasma yields inhibitor eoncentrations whieh are to~ low. For 
40KIU/mi the within-run imprecision was 1.8 - 10.8% in g 
scrics, thc between-series imprecision (n = 8)~.4 %. Thc recovery 
for 20 - 80KIU/ml was 90 - 125 %. The aCld-lreated sampIes 
were stable for at least 1 monlh at - 20°C and for 6 months at 
- 70°C. No innuencc by repeated freezing and thawing 
(10 times) eould be observed. Plasma sampies without acid 
treatment cannot be used bccause of a 100 high and irregular 
stimulation of the kallikrein activi ty in the assay system. 
Clinical ApplicQlion. Continuous i.v. infusion of 250,000 KIU/h 
in pOlytraumatizcd patients rcsulted in a mean plasma eon-
ccntration of 45 KI U/ml. This b 'eJ is equivalent 10 approx. I IlM 
aprolinin and thus elose to the concenlration of the endogenous 
lll-plasmin inhibitor level (0.9 ~M) in normal plasma. The 
aprotinin plasma level achievcd during inhibitor Iherapy caused 
a signifiea nt reduetion of the fibrinogcn split products eompared 
to untreated but equal1y severely injured patients indicating a 
bcneficial effeet by suppressing systemic fibrinolysis. 
Conclusion. Estimation of aprotinin in plasma with the describcd 
amidolytie assay ean bc aehieved wilhin 70 - 80min and is, 
thcrefore convenient as a bcds.ide-control of high dose pro-
teinase i~hibitor therapy. Morcover, an ELiSA for aprotinin 
dcve10ped simultaneously (MüllcT-Est~rl ~t al. this is~ue) ~llows 
the detection of up to 0.2KIU/ml wlthm 4h and lS sUltable, 
therefore, for special purposes, e.g. retrospective studies and low 
dose inhibitor therapy. 
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